Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 1, 2015 Sanjay Kumar	Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world.
Chemistry World April 22, 2015 Phillip Broadwith	Daiichi Sankyo steps out after Sun-Ranbaxy merger Japanese firm Daiichi Sankyo has sold off its entire stake in India's Sun Pharmaceuticals, following Sun's takeover of Indian rival Ranbaxy, in which Daiichi was the controlling shareholder.
Chemistry World April 9, 2014 Andy Extance	Sun set on Ranbaxy rescue India's Sun Pharma will acquire its compatriot Ranbaxy in a $3.2 billion all-share deal that will create the world's fourth largest generic drugs producer.
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
Chemistry World July 28, 2008 Rebecca Trager	Ranbaxy troubles place FDA under fire Indian drug firm Ranbaxy is facing scrutiny by American federal agencies and lawmakers over allegations that the company falsified scientific evidence to gain US approval for its products.
BusinessWeek July 14, 2003 Einhorn & Kripalani	In India a Little Lab Work and Lots of Lawyers Ranbaxy, a maker of generic drugs, must win lawsuits to grow
Chemistry World November 21, 2014 Rebecca Trager	Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
BusinessWeek January 12, 2004 Manjeet Kripalani	India: Big Pharma's New Promised Land? Drugmakers are heeding the siren call of its well-trained, cheap chemists.
Chemistry World May 3, 2012 Akshat Rathi	Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
The Motley Fool September 18, 2008 Brian Orelli	Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
Chemistry World June 13, 2008 Sarah Houlton	Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses.
Chemistry World February 2012	Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.
The Motley Fool January 5, 2005 Rich Smith	Mine Safety Digs Itself The company will buy back shares from the estate of the deceased mother of Mine Safety's chairman and CEO. Shares opened on the day of the announcement at $51.15. The company will buy these shares for just $46.36.
The Motley Fool February 26, 2009 Brian Orelli	Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association.
The Motley Fool August 19, 2011 Cindy Johnson	12 Pharmaceutical Stocks the Insiders Are Buying Folks in the know think these pharmaceutical stocks will rise. Should you join them?
Chemistry World August 21, 2015 Sa njay Kumar	Indian pharma under increased regulatory scrutiny A Europe-wide ban on hundreds of generic pharmaceutical formulations tested by Indian contract research firm GVK Biosciences comes into force today.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
Chemistry World January 27, 2014 Phillip Broadwith	US blocks imports from fourth Ranbaxy plant The US Food and Drug Administration has banned Indian drugmaker Ranbaxy from importing active pharmaceutical ingredients produced at its plant at Toansa, India, into the US.
InternetNews April 6, 2009 Paul Shread	Sun Walks Away From IBM Merger Talks IBM's acquisition of Sun could have apparently fallen apart, at least for now.
The Motley Fool June 29, 2009 Dan Caplinger	Is There Free Money In These Stocks? Sometimes, a bargain price on a stock seems to offer investors free money. If you don't understand the risks involved, though, attractive stocks can burn you.
The Motley Fool July 16, 2004 Tom Gardner	Martha Stewart, Was It Insider Trading? She was convicted of perjury, but did she make an illegal stock trade? Investment Intelligence from Insider Trading author weighs in.
The Motley Fool June 28, 2005 Lawrence Meyers	It's All Positive for PPDI Pharmaceutical Product Development continues to pump out the cash flow and rake in business. Investors, take note.
The Motley Fool March 29, 2005	What's a Hostile Takeover? Some companies need to look out for hostile takeovers.
BusinessWeek October 10, 2005 Manjeet Kripalani	India: A Quiet Shopping Spree So far, foreign companies being bought by Indian players are small - but that's likely to change
The Motley Fool August 1, 2011 Dan Caplinger	Stock-Dumping Insiders Shouldn't Scare You Corporate insiders are selling at a quick pace, but don't let it spook you.
Chemistry World October 17, 2014 Dinsa Sachan	Indian manufacturers hit back over quality claims The Indian pharmaceutical industry has asked its government to sue authors of a study published by the US National Bureau of Economic Research in early September.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool June 10, 2010	30% of Takeovers Are Dodgy As bid rumors lift ARM, the FSA warns of suspicious pre-takeover activity.
Chemistry World September 11, 2014 Emma Stoye	Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters.
The Motley Fool December 29, 2005 Rich Smith	Cheat, Profit, Go to Jail The FBI nabs one Charter One Financial/Royal Bank of Scotland insider trader, but its work isn't done.
Chemistry World September 18, 2008 James Mitchell Crow	Ranbaxy hit by US drug ban The US Food and Drug Administration (FDA) has banned the import of more than 30 drugs made by Ranbaxy, India's largest drugmaker.
The Motley Fool January 21, 2011 Esterhuizen & Sellitti	Smart Money: 15 Takeover Rumors Seeing Institutional Buying How can you tell which companies are wearing bulls-eyes on their backs?
The Motley Fool April 30, 2008 Brian Lawler	Pfizer Protects Profitable Patent The courts uphold a key patent on Pfizer's top drug.
The Motley Fool June 20, 2011 Cindy Johnson	11 Health-Care Stocks Insiders Are Buying What the insiders are doing can tell us a lot.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool July 1, 2011 Cindy Johnson	10 Bank Stocks Insiders Are Buying Insider buying is considered a good sign.
The Motley Fool August 25, 2011 Eben Esterhuizen	Bullish Insiders: Top 5 Insider Buys at Companies Reporting Earnings Next Week These insiders seem to think their companies are being underestimated -- will upcoming earnings result reflect insider optimism?
The Motley Fool July 1, 2011 Cindy Johnson	5 Consumer Services Stocks Insiders Are Buying Open-market insider buys are a positive sign.
The Motley Fool May 10, 2004 Rich Smith	When Cheating Is an Option The Charter One acquisition by Royal Bank of Scotland may spawn yet another insider-trading scandal.
The Motley Fool August 23, 2011 Cindy Johnson	13 Health-Care Equipment Stocks Insiders Are Buying Folks in the know think these stocks will rise. Should you join them?
Chemistry World October 23, 2013 Sarah Houlton	Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made.
The Motley Fool June 8, 2010 Tom Lydon	India ETFs: 5 Reasons the Tiger Is Roaring India has emerged from the economic recession as one of the strongest growth economies in the world.
The Motley Fool September 2, 2009 Dan Caplinger	Look Who's Dumping These 7 Stocks Insiders might be getting out while the getting is good.
The Motley Fool November 2, 2010 Esterhuizen & Sellitti	6 Takeover Targets Seeing Insider Buying These execs believe in the growth potential of their companies.